PRPO Quote, Financials, Valuation and Earnings

Azenta has a net margin of -12.02% compared to Precipio's net margin of -28.21%. Precipio's return on equity of -23.34% beat Azenta's return on equity of -3.48%.

Precipio has a consensus price target of --, signalling upside risk potential of 186.6%. On the other hand Azenta has an analysts' consensus of $41.00 which suggests that it could grow by 53.16%. Given that Precipio has higher upside potential than Azenta, analysts believe Precipio is more attractive than Azenta.

Precipio has a beta of 1.118, which suggesting that the stock is 11.833% more volatile than S&P 500. In comparison Azenta has a beta of 1.638, suggesting its more volatile than the S&P 500 by 63.767%.

Precipio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precipio pays -- of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend.

Precipio quarterly revenues are $5.2M, which are smaller than Azenta quarterly revenues of $143.4M. Precipio's net income of -$626K is higher than Azenta's net income of -$40.5M. Notably, Precipio's price-to-earnings ratio is -- while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precipio is 0.52x versus 2.03x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bionano Genomics has a net margin of -12.02% compared to Precipio's net margin of -728.57%. Precipio's return on equity of -23.34% beat Bionano Genomics's return on equity of -158.95%.

Precipio has a consensus price target of --, signalling upside risk potential of 186.6%. On the other hand Bionano Genomics has an analysts' consensus of $7.00 which suggests that it could grow by 82.51%. Given that Precipio has higher upside potential than Bionano Genomics, analysts believe Precipio is more attractive than Bionano Genomics.

Precipio has a beta of 1.118, which suggesting that the stock is 11.833% more volatile than S&P 500. In comparison Bionano Genomics has a beta of 2.367, suggesting its more volatile than the S&P 500 by 136.713%.

Precipio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precipio pays -- of its earnings as a dividend. Bionano Genomics pays out -- of its earnings as a dividend.

Precipio quarterly revenues are $5.2M, which are smaller than Bionano Genomics quarterly revenues of $6.1M. Precipio's net income of -$626K is higher than Bionano Genomics's net income of -$44.2M. Notably, Precipio's price-to-earnings ratio is -- while Bionano Genomics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precipio is 0.52x versus 0.09x for Bionano Genomics. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of -12.02% compared to Precipio's net margin of 2.17%. Precipio's return on equity of -23.34% beat Bruker's return on equity of 4.53%.

Precipio has a consensus price target of --, signalling upside risk potential of 186.6%. On the other hand Bruker has an analysts' consensus of $55.90 which suggests that it could grow by 48.99%. Given that Precipio has higher upside potential than Bruker, analysts believe Precipio is more attractive than Bruker.

Precipio has a beta of 1.118, which suggesting that the stock is 11.833% more volatile than S&P 500. In comparison Bruker has a beta of 1.228, suggesting its more volatile than the S&P 500 by 22.782%.

Precipio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.53% to investors and pays a quarterly dividend of $0.05 per share. Precipio pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Precipio quarterly revenues are $5.2M, which are smaller than Bruker quarterly revenues of $801.4M. Precipio's net income of -$626K is lower than Bruker's net income of $17.4M. Notably, Precipio's price-to-earnings ratio is -- while Bruker's PE ratio is 72.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precipio is 0.52x versus 1.64x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of -12.02% compared to Precipio's net margin of 0.07%. Precipio's return on equity of -23.34% beat Harvard Bioscience's return on equity of -18.36%.

Precipio has a consensus price target of --, signalling upside risk potential of 186.6%. On the other hand Harvard Bioscience has an analysts' consensus of $4.50 which suggests that it could grow by 1328.57%. Given that Harvard Bioscience has higher upside potential than Precipio, analysts believe Harvard Bioscience is more attractive than Precipio.

Precipio has a beta of 1.118, which suggesting that the stock is 11.833% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.441, suggesting its more volatile than the S&P 500 by 44.128%.

Precipio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Precipio pays -- of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend.

Precipio quarterly revenues are $5.2M, which are smaller than Harvard Bioscience quarterly revenues of $24.6M. Precipio's net income of -$626K is lower than Harvard Bioscience's net income of $18K. Notably, Precipio's price-to-earnings ratio is -- while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Precipio is 0.52x versus 0.15x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.